Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resistance and to design more effective therapeutic strategies. Conventional cancer treatments, including cytotoxic chemotherapy, radiation therapy, and targeted therapy, have immunomodulatory effects in addition to direct cancer cell-killing activities. Their clinical utilities in combination with ICIs have been explored, aiming to achieve synergetic effects with improved and durable clinical response. Here, we will review the immunomodulatory effects of chemotherapy, targeted therapy, and radiation therapy, in the setting of ICI, and their clinical implications in reshaping modern cancer immunotherapy.

Original languageEnglish (US)
Number of pages1
JournalFrontiers in Immunology
Volume9
DOIs
StatePublished - Jan 1 2018

Fingerprint

Neoplasms
Radiotherapy
Therapeutics
Drug Therapy
Immunomodulation
Immunotherapy

Keywords

  • chemotherapy
  • combination therapy
  • immunotherapy
  • radiotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. / Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi; Markovic, Svetomir Nenad; Park, Sean S; Dronca, Roxana S; Dong, Haidong M.

In: Frontiers in Immunology, Vol. 9, 01.01.2018.

Research output: Contribution to journalReview article

@article{ae7725c416e2482eb85db9c482609d74,
title = "Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy",
abstract = "Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resistance and to design more effective therapeutic strategies. Conventional cancer treatments, including cytotoxic chemotherapy, radiation therapy, and targeted therapy, have immunomodulatory effects in addition to direct cancer cell-killing activities. Their clinical utilities in combination with ICIs have been explored, aiming to achieve synergetic effects with improved and durable clinical response. Here, we will review the immunomodulatory effects of chemotherapy, targeted therapy, and radiation therapy, in the setting of ICI, and their clinical implications in reshaping modern cancer immunotherapy.",
keywords = "chemotherapy, combination therapy, immunotherapy, radiotherapy, targeted therapy",
author = "Yiyi Yan and Kumar, {Anagha Bangalore} and Heidi Finnes and Markovic, {Svetomir Nenad} and Park, {Sean S} and Dronca, {Roxana S} and Dong, {Haidong M}",
year = "2018",
month = "1",
day = "1",
doi = "10.3389/fimmu.2018.01739",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

AU - Yan, Yiyi

AU - Kumar, Anagha Bangalore

AU - Finnes, Heidi

AU - Markovic, Svetomir Nenad

AU - Park, Sean S

AU - Dronca, Roxana S

AU - Dong, Haidong M

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resistance and to design more effective therapeutic strategies. Conventional cancer treatments, including cytotoxic chemotherapy, radiation therapy, and targeted therapy, have immunomodulatory effects in addition to direct cancer cell-killing activities. Their clinical utilities in combination with ICIs have been explored, aiming to achieve synergetic effects with improved and durable clinical response. Here, we will review the immunomodulatory effects of chemotherapy, targeted therapy, and radiation therapy, in the setting of ICI, and their clinical implications in reshaping modern cancer immunotherapy.

AB - Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resistance and to design more effective therapeutic strategies. Conventional cancer treatments, including cytotoxic chemotherapy, radiation therapy, and targeted therapy, have immunomodulatory effects in addition to direct cancer cell-killing activities. Their clinical utilities in combination with ICIs have been explored, aiming to achieve synergetic effects with improved and durable clinical response. Here, we will review the immunomodulatory effects of chemotherapy, targeted therapy, and radiation therapy, in the setting of ICI, and their clinical implications in reshaping modern cancer immunotherapy.

KW - chemotherapy

KW - combination therapy

KW - immunotherapy

KW - radiotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85053187734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053187734&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.01739

DO - 10.3389/fimmu.2018.01739

M3 - Review article

C2 - 30100909

AN - SCOPUS:85053187734

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

ER -